Skip to main content

Table 2 Western blotting results for RAC1, homer 1, APP, STEP, NSE, and β-actin and their ratios in the cerebellar vermis a

From: Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex

 

Control

Autistic

Change

P-value

Cohen’s d

Adults

     

RAC1/β-actin

0.315 ± 0.206

1.3 ± 0.714

313%↑

0.025b

1.62b

Homer 1/β-actin

0.237 ± 0.303

0.147 ± 0.147

38%↓

ns

0.42

APP 120 kDa/β-actin

0.091 ± 0.029

0.050 ± 0.016

45%↓

0.018b

−2.04b

APP 88 kDa/β-actin

0.08 ± 0.06

0.03 ± 0.02

63%↓

ns

1.26

STEP 66 kDa/β-actin

0.136 ± 0.116

0.025 ± 0.029

82%↓

0.023b

−1.51b

STEP 61 kDa/β-actin

0.015 ± 0.028

0.003 ± 0.004

80%↓

ns

−0.67

STEP 46 kDa/β-actin

0.03 ± 0.034

0.034 ± 0.041

13%↑

ns

0.11

STEP 33 kDa/β-actin

0.55 ± 0.38

0.17 ± 0.13

69%↓

0.024b

−1.63b

STEP 27 kDa/β-actin

0.70 ± 0.67

0.53 ± 0.39

24%↓

ns

−0.32

β-actin

10.2 ± 1.67

9.06 ± 3.1

11%↓

ns

nd

Children

     

RAC1/β-actin

1.09 ± 0.545

1.1 ± 0.471

0.9%↑

ns

0.01

Homer 1/β-actin

0.188 ± 0.13

0.218 ± 0.109

16%↑

ns

0.26

APP 120 kDa/β-actin

0.071 ± 0.029

0.077 ± 0.033

8.4%↑

ns

0.19

APP 88 kDa/β-actin

0.084 ± 0.055

0.100 ± 0.071

19%↑

ns

0.25

STEP 66 kDa/β-actin

0.01 ± 0.008

0.059 ± 0.091

490%↑

ns

0.64

STEP 61 kDa/β-actin

0.002 ± 0.002

0.023 ± 0.031

1050%↑

ns

1.15

STEP 46 kDa/β-actin

0.0022 ± 0.0011

0.024 ± 0.024

991%↑

ns

1.16

STEP 33 kDa/β-actin

0.057 ± 0.085

0.13 ± 0.17

128%↑

ns

0.51

STEP 27 kDa/β-actin

0.70 ± 0.68

0.53 ± 0.38

24%↓

ns

−0.72

β-actin

9.48 ± 1.11

9.52 ± 3.71

0.4%↑

ns

nd

Adults

     

RAC1/NSE

0.23 ± 0.16

0.93 ± 0.49

304%↑

0.016b

1.73b

Homer 1/NSE

0.18 ± 0.24

0.099 ± 0.11

45%↓

ns

−0.46

APP 120 kDa/NSE

0.062 ± 0.021

0.031 ± 0.008

50%↓

0.012b

−2.40b

APP 88 kDa/NSE

0.06 ± 0.05

0.02 ± 0.01

67%↓

ns

−1.22

STEP 66 kDa/NSE

0.18 ± 0.14

0.032 ± 0.04

82%↓

0.018b

−1.59b

STEP 61 kDa/NSE

0.018 ± 0.035

0.004 ± 0.005

78%↓

ns

−0.21

STEP 46 kDa/NSE

0.039 ± 0.041

0.037 ± 0.042

5.1%↓

ns

−0.59

STEP 33 kDa/NSE

0.72 ± 0.49

0.21 ± 0.17

71%↓

0.020b

−1.68b

STEP 27 kDa/NSE

1.27 ± 0.82

0.44 ± 0.38

65%↓

0.038b

−1.40b

NSE

7.42 ± 1.26

7.69 ± 1.3

3.6%↑

ns

nd

Children

     

RAC1/NSE

0.84 ± 0.51

0.69 ± 0.23

18%↓

ns

−0.38

Homer 1/NSE

0.13 ± 0.09

0.16 ± 0.07

23%↑

ns

0.33

APP 120 kDa/NSE

0.040 ± 0.025

0.056 ± 0.021

40%↑

ns

0.70

APP 88 kDa/NSE

0.054 ± 0.025

0.072 ± 0.053

33%↑

ns

0.42

STEP 66 kDa/NSE

0.014 ± 0.011

0.102 ± 0.165

628%↑

ns

0.61

STEP 61 kDa/NSE

0.0024 ± 0.001

0.037 ± 0.054

1441%↑

ns

0.96

STEP 46 kDa/NSE

0.003 ± 0.002

0.03 ± 0.047

900%↑

ns

1.02

STEP 33 kDa/NSE

0.078 ± 0.12

0.23 ± 0.33

194%↑

ns

0.55

STEP 27 kDa/NSE

0.36 ± 0.24

0.99 ± 0.93

175%↑

ns

0.77

NSE

6.97 ± 0.84

6.23 ± 1.53

10.6%↓

ns

nd

  1. Values for control and autistic groups are presented as mean ± SD aRAC1, ras-related C3 botulinum toxin substrate 1; APP, amyloid beta A4 precursor protein; STEP, striatal-enriched protein tyrosine phosphatase; NSE, neuronal specific enolase; nd, not determined; ns, not significant. bStatistically significant.